The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway

Int Immunopharmacol. 2005 Mar;5(3):609-18. doi: 10.1016/j.intimp.2004.11.008.

Abstract

Recently, we have shown that various types of antidepressants, including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, have negative immunoregulatory effects. These antidepressants suppress the interferon-gamma (IFN-gamma)/interleukin-10 (IL-10) production ratio, which is of critical importance for the determination of the capacity of immunocytes to inhibit or activate monocytic/lymphocytic functions. Since cyclic adenosine monophosphate (cAMP) production is stimulated by some antidepressants, and since cAMP inhibits IFN-gamma and stimulates IL-10 production, we postulate that the negative immunoregulatory effects of antidepressants result from their effects on the cAMP-dependent protein kinase A (PKA) pathway. The aim of the present study was to determine whether the negative immunoregulatory effects of fluoxetine may be blocked by antagonists of the cAMP-dependent PKA pathway, such as, e.g., SQ 22536, an adenylate cyclase inhibitor, and Rp-8-Br-cAMPs (Rp-isomer of 8-bromo-adenosine-3',5'-monophosphorothioate), a PKA antagonist. To this end, diluted whole blood collected from 17 normal volunteers was incubated with fluoxetine (10(-6) and 10(-5) M), with or without SQ 22536 (10(-6) and 10(-4) M) and Rp-8-Br-cAMPs (10(-6) and 10(-4) M), afterwards, IFN-gamma, IL-10 and the tumor necrosis factor alpha (TNF-alpha) were determined. Fluoxetine, 10(-6) and 10(-5) M, significantly reduced the production of IFN-gamma and TNF-alpha, and significantly decreased the IFN-gamma/IL-10 production ratio. SQ 22536 and Rp-8-Br-cAMPs were unable to block the suppressant effects of fluoxetine on the IFN-gamma/IL-10 ratio. Rp-8-Br-cAMPs, 10(-4), but not 10(-6) M, normalized the fluoxetine-induced suppression of TNF-alpha production. It is concluded that the suppressant effect of fluoxetine on the IFN-gamma/IL-10 production ratio is probably not related to the induction of the cAMP-dependent PKA pathway, whereas the suppressant effect on TNF-alpha may be related to the induction of PKA. The obtained results suggest that increased activation of the PKA-dependent pathway may constitute an important molecular basis for some (suppression of TNF-alpha production), but not all (suppression of IFN-gamma production), negative immunoregulatory effects of fluoxetine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Bromo Cyclic Adenosine Monophosphate / analogs & derivatives
  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adult
  • Cyclic AMP / physiology*
  • Cyclic AMP-Dependent Protein Kinase Type II
  • Cyclic AMP-Dependent Protein Kinases / blood
  • Cyclic AMP-Dependent Protein Kinases / physiology*
  • Enzyme Inhibitors / pharmacology
  • Female
  • Fluoxetine / pharmacology*
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • In Vitro Techniques
  • Interferon-gamma / blood
  • Interleukin-10 / blood
  • Lipopolysaccharides / pharmacology
  • Male
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Thionucleotides / pharmacology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • 8-bromoadenosine-3',5'-cyclic monophosphorothioate
  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Lipopolysaccharides
  • Protein Kinase Inhibitors
  • Thionucleotides
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide, E. coli O26-B6
  • Fluoxetine
  • Interleukin-10
  • 9-(tetrahydro-2-furyl)-adenine
  • 8-Bromo Cyclic Adenosine Monophosphate
  • Interferon-gamma
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinase Type II
  • Cyclic AMP-Dependent Protein Kinases
  • Adenine